Last reviewed · How we verify

NovaBay Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

NovaBay Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 7 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Armata Pharmaceuticals, Inc. · 1 shared drug class
  2. Krishnadevaraya College of Dental Sciences & Hospital · 1 shared drug class
  3. Riyadh Colleges of Dentistry and Pharmacy · 1 shared drug class
  4. SIFI SpA · 1 shared drug class
  5. Savara Inc. · 1 shared drug class
  6. Universitair Ziekenhuis Brussel · 1 shared drug class
  7. University of Guarulhos · 1 shared drug class
  8. VA Office of Research and Development · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NovaBay Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). NovaBay Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novabay-pharmaceuticals-inc. Accessed 2026-05-16.

Related